Astec Life Sciences Ltd. shares gained nearly 3% in early trading today, currently priced at ₹935.10, reflecting a rise of ₹20.80 from the previous close of ₹914.30. The stock reached a day’s high of ₹940, with a market capitalization of ₹1,817 crore. The company’s strong sales growth and narrowing operational losses contributed to the positive market sentiment.
For the quarter ended December 2024, Astec Life Sciences reported a significant 84.8% YoY increase in sales to ₹93.86 crore, compared to ₹50.79 crore in the corresponding quarter of the previous fiscal. Despite this, the company posted a net loss of ₹40.38 crore, deepening from the ₹24.33 crore loss in the same period last year, driven by ongoing challenges in operational efficiency.
Astec Life Sciences reported strong sales growth of 84.8% YoY in Q3 FY25, reaching ₹93.86 crore compared to ₹50.79 crore in the same period last year. The company’s operating profit margin improved significantly, narrowing to -6.12% from -36.09% YoY. Losses before depreciation and tax reduced by 42% to ₹13.75 crore from ₹23.52 crore, while pre-tax losses also narrowed to ₹25.15 crore from ₹32.22 crore. Despite these improvements, the company posted a net loss of ₹40.38 crore, deepening from ₹24.33 crore in the previous fiscal quarter. These results reflect Astec’s ongoing efforts to address operational challenges while benefiting from increased demand for its products.
Astec Life Sciences’ operational performance saw improvements, as reflected in better margins and reduced pre-tax losses. The company attributed the robust sales growth to increased demand for its specialty chemicals and agrochemical intermediates. However, the company continues to grapple with high input costs and operational challenges, which have weighed on profitability.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.
